CryoLife Inc. (NYSE:CRY) reached a new 52-week high during trading on Monday . The stock traded as high as $15.97 and last traded at $15.86, with a volume of 197,966 shares trading hands. The stock had previously closed at $15.51.

Several equities research analysts recently commented on CRY shares. Piper Jaffray Cos. reaffirmed an “overweight” rating and issued a $15.00 price objective on shares of CryoLife in a research report on Thursday, April 21st. Ladenburg Thalmann cut shares of CryoLife from a “buy” rating to a “neutral” rating and set a $12.00 price objective on the stock. in a research report on Thursday, April 28th. They noted that the move was a valuation call. Lake Street Capital began coverage on shares of CryoLife in a research report on Wednesday, June 15th. They set a “buy” rating and a $15.00 price target on the stock. Canaccord Genuity reissued a “buy” rating on shares of CryoLife in a research report on Monday, June 20th. Finally, Zacks Investment Research cut shares of CryoLife from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, July 5th. One analyst has rated the stock with a hold rating, four have given a buy rating and one has issued a strong buy rating to the company. The stock has an average rating of “Buy” and an average price target of $15.00.

The stock has a market cap of $541.33 million and a P/E ratio of 50.87. The firm has a 50-day moving average of $13.09 and a 200-day moving average of $11.68.

CryoLife (NYSE:CRY) last posted its quarterly earnings data on Monday, July 25th. The company reported $0.13 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $0.02 by $0.11. The firm had revenue of $47.10 million for the quarter, compared to analyst estimates of $35.50 million. During the same quarter last year, the company earned $0.03 earnings per share. The company’s quarterly revenue was up 32.6% compared to the same quarter last year. Equities research analysts predict that CryoLife Inc. will post $0.24 earnings per share for the current fiscal year.

In other news, Director C Elkins Ronald sold 2,000 shares of the stock in a transaction on Tuesday, July 26th. The shares were sold at an average price of $14.00, for a total transaction of $28,000.00. Following the completion of the sale, the director now directly owns 103,586 shares in the company, valued at $1,450,204. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, Director Ronald D. Mccall sold 10,000 shares of the stock in a transaction on Wednesday, June 1st. The stock was sold at an average price of $11.56, for a total transaction of $115,600.00. Following the sale, the director now owns 156,248 shares of the company’s stock, valued at $1,806,226.88. The disclosure for this sale can be found here.

An institutional investor recently raised its position in CryoLife stock. Morgan Stanley boosted its stake in CryoLife Inc. (NYSE:CRY) by 1.3% during the fourth quarter, according to its most recent disclosure with the SEC. The fund owned 1,605,563 shares of the company’s stock after buying an additional 21,067 shares during the period. Morgan Stanley owned approximately 5.64% of CryoLife worth $17,308,000 at the end of the most recent reporting period.

CryoLife, Inc (CryoLife) is engaged in medical device manufacturing and distribution, and in the processing and distribution of implantable human tissues for cardiac and vascular surgeries. The Company operates in two segments: Medical Devices and Preservation Services. The Medical Devices segment sells BioGlue, BioFoam, PerClot, CardioGenesis cardiac laser therapy, Hemodialysis Reliable Outflow (HeRO) Graft, and ProCol Vascular Bioprosthesis (ProCol).

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.